BE2013C035I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2013C035I2 BE2013C035I2 BE2013C035C BE2013C035C BE2013C035I2 BE 2013C035 I2 BE2013C035 I2 BE 2013C035I2 BE 2013C035 C BE2013C035 C BE 2013C035C BE 2013C035 C BE2013C035 C BE 2013C035C BE 2013C035 I2 BE2013C035 I2 BE 2013C035I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200301129 | 2003-08-05 | ||
| US49545103P | 2003-08-14 | 2003-08-14 | |
| EP04739008A EP1660531A2 (en) | 2003-08-05 | 2004-07-22 | Novel insulin derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2013C035I2 true BE2013C035I2 (en:Method) | 2023-12-14 |
Family
ID=34117520
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2013C035C BE2013C035I2 (en:Method) | 2003-08-05 | 2013-06-11 | |
| BE2013C038C BE2013C038I2 (en:Method) | 2003-08-05 | 2013-06-19 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2013C038C BE2013C038I2 (en:Method) | 2003-08-05 | 2013-06-19 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US7615532B2 (en:Method) |
| EP (3) | EP2264065B1 (en:Method) |
| JP (1) | JP4463814B2 (en:Method) |
| KR (1) | KR101159559B1 (en:Method) |
| AU (2) | AU2004261353B2 (en:Method) |
| BE (2) | BE2013C035I2 (en:Method) |
| BR (1) | BRPI0413276B8 (en:Method) |
| CA (1) | CA2531988C (en:Method) |
| CY (5) | CY1113850T1 (en:Method) |
| FR (2) | FR13C0035I2 (en:Method) |
| HU (1) | HUS1300033I1 (en:Method) |
| IL (1) | IL172980A (en:Method) |
| LU (2) | LU92213I2 (en:Method) |
| MX (1) | MXPA06001283A (en:Method) |
| NO (5) | NO340925B1 (en:Method) |
| PL (1) | PL2107069T3 (en:Method) |
| RU (1) | RU2518460C2 (en:Method) |
| WO (1) | WO2005012347A2 (en:Method) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060241019A1 (en) * | 2003-07-25 | 2006-10-26 | Bridon Dominique P | Long lasting insulin derivatives and methods thereof |
| KR101159559B1 (ko) * | 2003-08-05 | 2012-06-26 | 노보 노르디스크 에이/에스 | 신규의 인슐린 유도체 |
| ES2435522T3 (es) | 2005-02-02 | 2013-12-20 | Novo Nordisk A/S | Derivados de insulina |
| JP4933455B2 (ja) * | 2005-02-02 | 2012-05-16 | ノヴォ ノルディスク アー／エス | 新規のインスリン誘導体 |
| PT1969004E (pt) | 2005-12-28 | 2011-11-25 | Novo Nordisk As | Composições que compreendem uma insulina acilada e zinco e método para criar tais composições |
| EP1991576B1 (en) | 2006-02-27 | 2010-09-29 | Novo Nordisk A/S | Insulin derivatives |
| WO2007104736A2 (en) * | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
| WO2007127236A2 (en) | 2006-04-28 | 2007-11-08 | Acrymed, Inc. | Antimicrobial site dressings |
| CN101437849B (zh) * | 2006-05-09 | 2015-09-30 | 诺沃-诺迪斯克有限公司 | 胰岛素衍生物 |
| MX2008014061A (es) * | 2006-05-09 | 2008-11-14 | Novo Nordisk As | Derivado de insulina. |
| EP2024390B1 (en) | 2006-05-09 | 2015-08-19 | Novo Nordisk A/S | Insulin derivative |
| JP5097900B2 (ja) * | 2006-06-27 | 2012-12-12 | 独立行政法人物質・材料研究機構 | 有機酸又はこれらの誘導体の活性エステル体の製造方法 |
| WO2008015099A2 (en) | 2006-07-31 | 2008-02-07 | Novo Nordisk A/S | Pegylated, extended insulins |
| WO2008034881A1 (en) | 2006-09-22 | 2008-03-27 | Novo Nordisk A/S | Protease resistant insulin analogues |
| JP5496082B2 (ja) | 2007-04-30 | 2014-05-21 | ノボ・ノルデイスク・エー／エス | タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物 |
| EP2164466A1 (en) | 2007-06-01 | 2010-03-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
| EP2164458A1 (en) * | 2007-06-01 | 2010-03-24 | Novo Nordisk A/S | Stable non-aqueous pharmaceutical compositions |
| WO2008152106A1 (en) | 2007-06-13 | 2008-12-18 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
| CN101784563B (zh) * | 2007-08-15 | 2015-02-04 | 诺沃-诺迪斯克有限公司 | 具有包括含亚烷基二醇的氨基酸的重复单位的酰基部分的胰岛素 |
| CN101784562B (zh) | 2007-08-15 | 2016-07-13 | 诺沃-诺迪斯克有限公司 | 具有酰基和亚烷基二醇部分的胰岛素类似物 |
| CN101157725B (zh) * | 2007-10-24 | 2012-07-25 | 中国药科大学 | 人胰岛素类似物的制备方法及用途 |
| EP2217621B1 (en) | 2007-11-08 | 2015-04-22 | Novo Nordisk A/S | Insulin derivative |
| BRPI0820535B8 (pt) | 2007-11-16 | 2021-05-25 | Novo Nordisk As | composições farmacêuticas contendo insulina e um peptídeo insulinotrópico |
| JP5762001B2 (ja) | 2008-03-14 | 2015-08-12 | ノボ・ノルデイスク・エー／エス | プロテアーゼ安定化インスリンアナログ |
| RU2571857C2 (ru) | 2008-03-18 | 2015-12-20 | Ново Нордиск А/С | Стабилизированные по отношению к протеазам ацилированные аналоги инсулина |
| JP5591243B2 (ja) | 2008-09-12 | 2014-09-17 | ノボ・ノルデイスク・エー／エス | ペプチド又はタンパク質のアシル化の方法 |
| US9603904B2 (en) * | 2008-10-30 | 2017-03-28 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| WO2010084169A2 (en) | 2009-01-23 | 2010-07-29 | Novo Nordisk A/S | Fgf21 derivatives with albumin binder a-b-c-d-e- and their use |
| CN102666579A (zh) | 2009-10-30 | 2012-09-12 | 诺沃—诺迪斯克有限公司 | 降钙素基因相关肽的衍生物 |
| AU2011206629B2 (en) * | 2010-01-12 | 2014-07-17 | Novo Nordisk A/S | Pharmaceutical compositions for oral administration of insulin peptides |
| WO2011101261A2 (en) | 2010-02-16 | 2011-08-25 | Novo Nordisk A/S | Purification method |
| CN102812039B (zh) | 2010-02-16 | 2016-01-20 | 诺沃—诺迪斯克有限公司 | 缀合蛋白质 |
| WO2011141407A1 (en) | 2010-05-10 | 2011-11-17 | Novo Nordisk A/S | Process for the preparation of insulin-zinc complexes |
| EP2576612A4 (en) | 2010-05-25 | 2014-07-09 | Syngene Ltd | INSULIN ANALOG |
| EP2585483A1 (en) | 2010-06-23 | 2013-05-01 | Novo Nordisk A/S | Human insulin containing additional disulfide bonds |
| US8815798B2 (en) | 2010-06-23 | 2014-08-26 | Novo Nordisk A/S | Insulin analogues containing additional disulfide bonds |
| WO2011161125A1 (en) * | 2010-06-23 | 2011-12-29 | Novo Nordisk A/S | Insulin derivatives containing additional disulfide bonds |
| CN103154024A (zh) | 2010-10-15 | 2013-06-12 | 诺沃—诺迪斯克有限公司 | 新型n末端修饰的胰岛素衍生物 |
| BR112013010345A2 (pt) * | 2010-10-27 | 2017-07-25 | Novo Nordisk As | tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção |
| CA2815419A1 (en) | 2010-10-27 | 2012-05-03 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections administered with varying injection intervals |
| EP2651432A1 (en) | 2010-12-14 | 2013-10-23 | Novo Nordisk A/S | Fast-acting insulin in combination with long-acting insulin |
| EP2675470A1 (en) | 2011-02-15 | 2013-12-25 | Novo Nordisk A/S | Long-acting il-1 receptor antagonists |
| KR20140020292A (ko) * | 2011-03-28 | 2014-02-18 | 노보 노르디스크 에이/에스 | 신규 글루카곤 유사체 |
| EP2696847A1 (en) | 2011-04-14 | 2014-02-19 | Novo Nordisk A/S | Fatty acid acylated amino acids for oral peptide delivery |
| WO2012171994A1 (en) | 2011-06-15 | 2012-12-20 | Novo Nordisk A/S | Multi substituted insulins |
| MX354705B (es) * | 2011-09-23 | 2018-03-16 | Novo Nordisk As | Analogos de glucagon novedosos. |
| KR20140104994A (ko) * | 2011-12-15 | 2014-08-29 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | 인간 인슐린 유사체 및 이의 아실화 유도체 |
| CN104364262A (zh) | 2011-12-21 | 2015-02-18 | 诺沃—诺迪斯克有限公司 | N末端修饰的胰岛素衍生物 |
| JP6199956B2 (ja) | 2012-04-11 | 2017-09-20 | ノヴォ ノルディスク アー／エス | インスリン製剤 |
| US20160031962A1 (en) * | 2012-04-20 | 2016-02-04 | Kleomenis K. Barlos | Solid phase peptide synthesis of insulin using side chain achored lysine |
| AU2013255880B2 (en) | 2012-05-01 | 2017-07-20 | Novo Nordisk A/S | Pharmaceutical composition |
| WO2014009316A1 (en) | 2012-07-09 | 2014-01-16 | Novo Nordisk A/S | Novel use of insulin derivatives |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| JP6285447B2 (ja) | 2012-10-17 | 2018-02-28 | ノヴォ ノルディスク アー／エス | 経口ペプチド送達用の脂肪酸アシル化ｄ−アミノ酸 |
| SG10201705097PA (en) | 2012-12-21 | 2017-07-28 | Sanofi Sa | Functionalized exendin-4 derivatives |
| EP2976096B1 (en) * | 2013-03-20 | 2019-02-27 | Novo Nordisk A/S | Insulin dosing regimen |
| RU2683039C2 (ru) | 2013-04-18 | 2019-03-26 | Ново Нордиск А/С | Стабильные совместные агонисты рецептора глюкагоноподобного пептида-1/глюкагона пролонгированного действия для медицинского применения |
| US10137172B2 (en) | 2013-04-30 | 2018-11-27 | Novo Nordisk A/S | Administration regime |
| GB201315335D0 (en) | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
| SI3055325T1 (en) | 2013-10-07 | 2018-05-31 | Novo Nordisk A/S | NEW DERIVATIVE ANALOGUE INSULINE |
| FR3013049B1 (fr) | 2013-11-14 | 2015-11-13 | You-Ping Chan | Analogue de l'insuline glargine |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| AU2015220909A1 (en) | 2014-02-18 | 2016-07-14 | Novo Nordisk A/S | Stable glucagon analogues and use for treatment of hypoglycaemia |
| AR099569A1 (es) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| EP3151852A1 (en) | 2014-06-04 | 2017-04-12 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| US20180244743A1 (en) | 2015-08-25 | 2018-08-30 | Novo Nordisk A/S | Novel Insulin Derivatives and the Medical Uses Hereof |
| US20190010206A1 (en) | 2015-08-25 | 2019-01-10 | Novo Nordisk A/S | Novel Insulin Derivatives and the Medical Uses Hereof |
| CN108463468B (zh) * | 2016-08-02 | 2022-03-04 | 江苏恒瑞医药股份有限公司 | 一种人胰岛素或其类似物的酰化衍生物 |
| WO2018096164A1 (en) | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec for treating diabetes |
| MA46897A (fr) | 2016-11-28 | 2021-04-28 | Novo Nordisk As | Insuline dégludec utilisée dans des conditions cardiovasculaires |
| WO2018096163A1 (en) | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications |
| EP3554534B1 (en) | 2016-12-16 | 2021-06-23 | Novo Nordisk A/S | Insulin containing pharmaceutical compositions |
| JOP20190273A1 (ar) * | 2017-05-26 | 2019-11-24 | Lilly Co Eli | مركب إنسولين معالج بأسيل |
| CA3086618A1 (en) | 2018-02-09 | 2019-08-15 | Jiangsu Hengrul Medicine Co., Ltd. | Codon optimized precursor gene and signal peptide gene of human insulin analogue |
| JP2021524464A (ja) | 2018-05-24 | 2021-09-13 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． | 組換えヒトインスリンまたはそのアナログの前駆体の調製方法 |
| US20220023391A1 (en) | 2018-06-26 | 2022-01-27 | Novo Nordisk A/S | System providing dose recommendations for basal insulin titration |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| KR102666154B1 (ko) | 2018-08-08 | 2024-05-20 | 주식회사 대웅제약 | 지속형 인슐린 아날로그 및 그 복합체 |
| KR20200080747A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법 |
| KR20200080748A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법 |
| JP7518149B2 (ja) | 2019-07-12 | 2024-07-17 | ノヴォ ノルディスク アー／エス | 高濃度インスリン製剤 |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| CN118772259A (zh) | 2019-12-30 | 2024-10-15 | 甘李药业股份有限公司 | 胰岛素衍生物 |
| CA3177905A1 (en) | 2020-05-15 | 2021-11-18 | Eli Lilly And Company | Extended time action acylated insulin compounds |
| EP4433093A1 (en) | 2021-11-15 | 2024-09-25 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| CN118574842A (zh) | 2022-01-28 | 2024-08-30 | 甘李药业股份有限公司 | 酰化胰岛素 |
| EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
| WO2025104600A1 (en) * | 2023-11-15 | 2025-05-22 | Ambio, Inc. | Insulin analogs for the treatment of human metabolic disorder and disease |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1212679B (de) | 1957-08-03 | 1966-03-17 | Novo Terapeutisk Labor As | Verfahren zur Herstellung von Insulinloesungen |
| GB1042194A (en) | 1962-04-30 | 1966-09-14 | Olin Mathieson | Insulin preparations |
| US3528960A (en) | 1968-10-07 | 1970-09-15 | Lilly Co Eli | N-carboxyaroyl insulins |
| US3868358A (en) * | 1971-04-30 | 1975-02-25 | Lilly Co Eli | Protamine-insulin product |
| GB1492997A (en) | 1976-07-21 | 1977-11-23 | Nat Res Dev | Insulin derivatives |
| JPS5767548A (en) | 1980-10-14 | 1982-04-24 | Shionogi & Co Ltd | Insulin analog and its preparation |
| FI78616C (fi) * | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| NZ222907A (en) | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
| US5605884A (en) * | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
| US4877608A (en) | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
| JPH01254699A (ja) | 1988-04-05 | 1989-10-11 | Kodama Kk | インスリン誘導体及びその用途 |
| DE3827533A1 (de) * | 1988-08-13 | 1990-02-15 | Hoechst Ag | Pharmazeutische zubereitung zur behandlung des diabetes mellitus |
| AU641631B2 (en) | 1988-12-23 | 1993-09-30 | Novo Nordisk A/S | Human insulin analogues |
| NZ232375A (en) | 1989-02-09 | 1992-04-28 | Lilly Co Eli | Insulin analogues modified at b29 |
| IT1240314B (it) | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | Formulazioni acquose stabilizzate di piccoli peptidi. |
| US5382574A (en) * | 1989-12-21 | 1995-01-17 | Novo Nordisk A/S | Insulin preparations containing nicotinic acid or nicotinamide |
| DK45590D0 (en:Method) | 1990-02-21 | 1990-02-21 | Novo Nordisk As | |
| JP3193398B2 (ja) | 1991-07-23 | 2001-07-30 | サンデン株式会社 | ショ−ケ−ス |
| HUT69402A (en) | 1991-12-20 | 1995-09-28 | Novo Nordisk As | Process for producing stabilized pharmaceutical formulations comprising growth hormone and histidine |
| US6869930B1 (en) * | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| US6011007A (en) * | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| EP1132404A3 (en) | 1993-09-17 | 2002-03-27 | Novo Nordisk A/S | Acylated insulin |
| US5652216A (en) | 1994-05-26 | 1997-07-29 | Novo Nordisk A/S | Pharmaceutical preparation |
| AU3562195A (en) | 1994-10-04 | 1996-04-26 | Novo Nordisk A/S | Preparations containing aspb28 human insulin and nicotinamide |
| US5646242A (en) * | 1994-11-17 | 1997-07-08 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
| US5830999A (en) * | 1995-01-26 | 1998-11-03 | Regents Of The University Of California | Stabilization of insulin through ligand binding interations |
| PL183698B1 (pl) | 1995-03-17 | 2002-06-28 | Novo Nordisk As | Pochodna insuliny, kompozycja farmaceutyczna i zastosowanie pochodnej insuliny |
| US6251856B1 (en) * | 1995-03-17 | 2001-06-26 | Novo Nordisk A/S | Insulin derivatives |
| JPH11510170A (ja) | 1995-07-27 | 1999-09-07 | ジェネンテック インコーポレーテッド | タンパク質の処方 |
| US6451970B1 (en) * | 1996-02-21 | 2002-09-17 | Novo Nordisk A/S | Peptide derivatives |
| US5898267A (en) * | 1996-04-10 | 1999-04-27 | Mcdermott; Kevin | Parabolic axial lighting device |
| US5866538A (en) * | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| US5905140A (en) * | 1996-07-11 | 1999-05-18 | Novo Nordisk A/S, Novo Alle | Selective acylation method |
| PT938502E (pt) * | 1996-07-11 | 2005-02-28 | Novo Nordisk As | Metodo selectivo por acilacao |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| ATE264871T1 (de) * | 1996-07-26 | 2004-05-15 | Aventis Pharma Gmbh | Insulinderivate mit erhöhter zinkbindung |
| IL119029A0 (en) * | 1996-08-07 | 1996-11-14 | Yeda Res & Dev | Long-acting drugs and pharamaceutical compositions comprising them |
| US5898067A (en) * | 1997-02-07 | 1999-04-27 | Novo Nordisk A/S | Crystallization of proteins |
| CN1259142A (zh) * | 1997-03-20 | 2000-07-05 | 诺沃挪第克公司 | 用于肺部的无锌胰岛素结晶组合物 |
| ATE219942T1 (de) | 1997-03-20 | 2002-07-15 | Novo Nordisk As | Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält |
| AU6611898A (en) | 1997-03-20 | 1998-10-20 | Novo Nordisk A/S | Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer |
| US7097845B2 (en) | 1997-04-23 | 2006-08-29 | Jacob Sten Petersen | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
| EP1283051B1 (en) | 1997-06-13 | 2006-06-14 | Eli Lilly And Company | Stable insulin formulations |
| JP2001521004A (ja) | 1997-10-24 | 2001-11-06 | イーライ・リリー・アンド・カンパニー | 脂肪酸−アシル化インスリン類似体 |
| UA69393C2 (uk) * | 1997-10-24 | 2004-09-15 | Ново Нордіск А/С | Водорозчинний агрегат похідної інсуліну |
| US6451762B1 (en) * | 1997-10-24 | 2002-09-17 | Novo Nordisk A/S | Aggregates of human insulin derivatives |
| US20020155994A1 (en) * | 1997-10-24 | 2002-10-24 | Svend Havelund | Aggregates of human insulin derivatives |
| ZA989744B (en) * | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| CO4970787A1 (es) | 1997-12-23 | 2000-11-07 | Lilly Co Eli | Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea |
| AU1870099A (en) * | 1998-01-09 | 1999-07-26 | Novo Nordisk A/S | Stabilised insulin compositions |
| PL197504B1 (pl) | 1998-10-16 | 2008-04-30 | Novo Nordisk As | Trwałe stężone preparaty insulinowe do podawania do płuc |
| US6211144B1 (en) * | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
| CA2634664C (en) * | 1999-02-22 | 2011-08-09 | University Of Connecticut | Novel albumin-free factor viii formulations |
| JP2002543092A (ja) | 1999-04-27 | 2002-12-17 | イーライ・リリー・アンド・カンパニー | 肺投与用インスリン結晶 |
| GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
| DE10022092A1 (de) | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| US6652886B2 (en) * | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| JP5562510B2 (ja) | 2001-06-28 | 2014-07-30 | ノヴォ ノルディスク アー／エス | 修飾ｇｌｐ−１の安定な処方剤 |
| KR20040070237A (ko) | 2001-12-20 | 2004-08-06 | 일라이 릴리 앤드 캄파니 | 연장된 작용 시간을 갖는 인슐린 분자 |
| US8003605B2 (en) * | 2002-03-13 | 2011-08-23 | Novo Nordisk A/S | Minimising body weight gain in insulin treatment |
| DE60335797D1 (de) * | 2002-05-07 | 2011-03-03 | Novo Nordisk As | Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten |
| US20050232899A1 (en) * | 2002-05-31 | 2005-10-20 | Aradigm Corporation | Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
| US20040002451A1 (en) * | 2002-06-20 | 2004-01-01 | Bruce Kerwin | Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing |
| KR100615389B1 (ko) | 2002-08-23 | 2006-08-25 | (주)헬릭서 | 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품 |
| KR20050083841A (ko) | 2002-10-29 | 2005-08-26 | 알자 코포레이션 | 안정화된 고체상태 폴리펩타이드 입자 |
| US20040138099A1 (en) * | 2002-11-29 | 2004-07-15 | Draeger Eberhard Kurt | Insulin administration regimens for the treatment of subjects with diabetes |
| CN101822834A (zh) | 2003-02-07 | 2010-09-08 | 味之素株式会社 | 糖尿病治疗药 |
| PT1597367E (pt) | 2003-02-19 | 2010-09-02 | Scripps Research Inst | Antigénio glicoproteína sima 135 expresso em células tumorais humanas metastáticas |
| US7544656B2 (en) * | 2003-03-04 | 2009-06-09 | The Technology Development Company, Ltd. | Long acting injectable insulin composition and methods of making and using thereof |
| WO2004112828A1 (en) | 2003-06-25 | 2004-12-29 | Novo Nordisk Health Care Ag | Liquid composition of factor vii polypeptides |
| US20050054818A1 (en) * | 2003-07-02 | 2005-03-10 | Brader Mark Laurence | Crystalline compositions for controlling blood glucose |
| KR101159559B1 (ko) * | 2003-08-05 | 2012-06-26 | 노보 노르디스크 에이/에스 | 신규의 인슐린 유도체 |
| KR101186851B1 (ko) | 2003-08-05 | 2012-10-02 | 노보 노르디스크 에이/에스 | 신규의 인슐린 유도체 |
| RU2388460C2 (ru) | 2003-08-14 | 2010-05-10 | Ново Нордиск Хелс Кеа Аг | Жидкая водная фармацевтическая композиция, содержащая полипептид фактора vii |
| EP1663295A2 (en) | 2003-09-01 | 2006-06-07 | Novo Nordisk A/S | Stable formulations of peptides |
| ES2229931B1 (es) * | 2003-10-03 | 2006-01-16 | Grifols, S.A. | Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos. |
| EP1687428A1 (en) * | 2003-11-14 | 2006-08-09 | Novo Nordisk A/S | Processes for making acylated insulin |
| ATE554792T1 (de) | 2003-12-23 | 2012-05-15 | Pharmacia Corp | Stabiles wachstumshormon-flüssigformulierung |
| DK1740154T3 (da) | 2004-03-12 | 2009-08-31 | Biodel Inc | Insulinsammensætninger med forbedret absorption |
| ES2381674T3 (es) | 2004-06-01 | 2012-05-30 | Ares Trading S.A. | Método de estabilizar proteínas |
| WO2006020720A2 (en) | 2004-08-12 | 2006-02-23 | Schering Corporation | Stable pegylated interferon formulation |
| AU2005277357B2 (en) | 2004-08-17 | 2011-08-04 | Regeneron Pharmaceuticals, Inc. | IL-1 antagonist formulations |
| JP5248113B2 (ja) | 2004-11-12 | 2013-07-31 | ノヴォ ノルディスク アー／エス | ペプチドの安定な処方 |
| CN101060856B (zh) | 2004-11-22 | 2011-01-19 | 诺和诺德公司 | 可溶、稳定的含胰岛素制剂 |
| CN101106979A (zh) | 2005-01-21 | 2008-01-16 | 阿尔扎公司 | 具有改善的稳定性的含有至少一种反离子的用于涂覆微针的治疗性的肽试剂 |
| JP4933455B2 (ja) * | 2005-02-02 | 2012-05-16 | ノヴォ ノルディスク アー／エス | 新規のインスリン誘導体 |
| PT1969004E (pt) | 2005-12-28 | 2011-11-25 | Novo Nordisk As | Composições que compreendem uma insulina acilada e zinco e método para criar tais composições |
| EP1991576B1 (en) * | 2006-02-27 | 2010-09-29 | Novo Nordisk A/S | Insulin derivatives |
| WO2007121256A2 (en) | 2006-04-12 | 2007-10-25 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
| MX2008014061A (es) * | 2006-05-09 | 2008-11-14 | Novo Nordisk As | Derivado de insulina. |
| WO2008152106A1 (en) * | 2007-06-13 | 2008-12-18 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
| BRPI0820535B8 (pt) * | 2007-11-16 | 2021-05-25 | Novo Nordisk As | composições farmacêuticas contendo insulina e um peptídeo insulinotrópico |
| TWI451876B (zh) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
-
2004
- 2004-07-22 KR KR1020067002551A patent/KR101159559B1/ko not_active Expired - Lifetime
- 2004-07-22 AU AU2004261353A patent/AU2004261353B2/en active Active
- 2004-07-22 PL PL09165072T patent/PL2107069T3/pl unknown
- 2004-07-22 JP JP2006522233A patent/JP4463814B2/ja not_active Expired - Lifetime
- 2004-07-22 MX MXPA06001283A patent/MXPA06001283A/es active IP Right Grant
- 2004-07-22 CA CA2531988A patent/CA2531988C/en not_active Expired - Fee Related
- 2004-07-22 EP EP10174490.2A patent/EP2264065B1/en not_active Expired - Lifetime
- 2004-07-22 WO PCT/DK2004/000511 patent/WO2005012347A2/en active Application Filing
- 2004-07-22 EP EP09165072A patent/EP2107069B1/en not_active Expired - Lifetime
- 2004-07-22 BR BRPI0413276A patent/BRPI0413276B8/pt active IP Right Grant
- 2004-07-22 EP EP04739008A patent/EP1660531A2/en not_active Withdrawn
-
2006
- 2006-01-05 IL IL172980A patent/IL172980A/en active Protection Beyond IP Right Term
- 2006-01-30 US US11/343,005 patent/US7615532B2/en active Active
- 2006-03-02 NO NO20061026A patent/NO340925B1/no active Protection Beyond IP Right Term
-
2008
- 2008-12-29 RU RU2008152033/04A patent/RU2518460C2/ru active
-
2009
- 2009-09-16 US US12/560,833 patent/US8828923B2/en not_active Expired - Lifetime
-
2010
- 2010-02-10 AU AU2010200497A patent/AU2010200497B2/en active Active
-
2013
- 2013-03-28 CY CY20131100259T patent/CY1113850T1/el unknown
- 2013-06-10 LU LU92213C patent/LU92213I2/fr unknown
- 2013-06-11 BE BE2013C035C patent/BE2013C035I2/fr unknown
- 2013-06-19 BE BE2013C038C patent/BE2013C038I2/fr unknown
- 2013-06-19 LU LU92226C patent/LU92226I2/xx unknown
- 2013-07-04 CY CY2013027C patent/CY2013027PI1/el unknown
- 2013-07-04 FR FR13C0035C patent/FR13C0035I2/fr active Active
- 2013-07-05 FR FR13C0038C patent/FR13C0038I1/fr active Active
- 2013-07-08 CY CY2013029C patent/CY2013029PI1/el unknown
- 2013-07-18 HU HUS1300033C patent/HUS1300033I1/hu unknown
-
2014
- 2014-08-06 US US14/453,276 patent/US20140349925A1/en not_active Abandoned
-
2018
- 2018-01-11 NO NO2018003C patent/NO2018003I1/no unknown
- 2018-01-11 NO NO2018002C patent/NO2018002I2/no unknown
-
2023
- 2023-12-28 CY CY2013029C patent/CY2013029I2/el unknown
-
2024
- 2024-01-16 NO NO2024003C patent/NO2024003I1/no unknown
- 2024-01-16 NO NO2024004C patent/NO2024004I1/no unknown
- 2024-01-31 CY CY2013027C patent/CY2013027I2/el unknown